A Record Of 1320 Suspect, Deferasirox-Related, Patient Deaths Reported In 2009: Insufficient Toxicity Testing, Low Efficacy And Lack Of Transparency May Endanger The Lives Of Iron Loaded Patients
- 20 May 2011
- journal article
- research article
- Published by Informa UK Limited in Hemoglobin
- Vol. 35 (3), 301-311
- https://doi.org/10.3109/03630269.2011.576906
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Iron Chelation Therapy in Hereditary Hemochromatosis and Thalassemia Intermedia: Regulatory and Non Regulatory Mechanisms of Increased Iron Absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251–264]Hemoglobin, 2011
- Iron Chelation Therapy in Hereditary Hemochromatosis and Thalassemia Intermedia: Regulatory and Non Regulatory Mechanisms of Increased Iron AbsorptionHemoglobin, 2010
- Pharmacokinetics, Distribution, Metabolism, and Excretion of Deferasirox and Its Iron Complex in RatsDrug Metabolism and Disposition, 2008
- Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disordersHaematologica, 2008
- Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/Deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of DeferasiroxHemoglobin, 2008
- Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.Hemoglobin, 2008
- Light and shadows in the iron chelation treatment of haematological diseasesBritish Journal of Haematology, 2007
- Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicitiesExpert Opinion on Drug Safety, 2007
- Do we need more iron-chelating drugs?The Lancet, 2003
- ICL670A: Preclinical ProfileAdvances in experimental medicine and biology, 2002